Legato Capital Management
FENC icon

Legato Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Legato Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.05M Buy
+98,325
New +$1.08M 0.09% 338
2024
Q2 		– Sell
-57,121
Closed -$635K – 584
2024
Q1 		$635K Buy
+57,121
New +$574K 0.08% 385

Other funds holding FENC

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Legato Capital Management's FENC Position: Q3 2026 in Review

Legato Capital Management opened a new position in Fennec Pharmaceuticals (FENC) in Q3 2026: 98,325 shares worth $1.05M. The stake represents 0.09% of the portfolio and ranks #338 among its holdings. This is a return to the name: Legato Capital Management previously reported a position in FENC as recently as Q1 2024.

Legato Capital Management first reported a position in FENC in Q1 2024 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold FENC as of Q3 2026.

  • Legato Capital Management held 98,325 shares of Fennec Pharmaceuticals worth $1.05M as of Q3 2026.
  • Fennec Pharmaceuticals was a new Legato Capital Management position in Q3 2026.
  • Fennec Pharmaceuticals made up 0.09% of Legato Capital Management's portfolio in Q3 2026, its #338 holding.
  • Legato Capital Management first reported a position in Fennec Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2026.

Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.